Should You Buy CVS Stock For The Margin Aetna Is Rebuilding?

CVS Health (CVS) keeps a little over a penny of profit from every dollar it takes in. A net margin of 1.2% reads like a verdict on the business. On $415.1 billion of revenue, one point of net margin is worth over $4 billion, and 1.2% is closer to a floor than a peak. Management has been working on it through 2026.

Why Does CVS Health Keep So Little Of What It Sells?

Among its closest peers, that margin sits at the low end. The best of them reach as high as 3.1%, roughly two and a half times CVS Health’s rate. Aetna is a separate story: management says the segment has been running under its target margins, and that it is on a pathway back to them over the next couple of years.

Through the first half of 2026 Aetna has delivered more than $2 billion of year-over-year improvement in adjusted operating income, on a full-year 2026 guidance of under $17 billion for the company as a whole.

Not all of the second-quarter strength was operating repair. A change in the individual exchange risk adjustment position and favorable prior year development contributed about $500 million, though management says core performance still beat expectations without those items.

What Is Pushing CVS Health’s Margin Back Up?

Two levers are doing the work. At Aetna, management has held pricing discipline, exited the individual exchange business, and leaned on medical cost management. Its Medicare business is now running ahead of the company’s own expectations, and management calls the improvement the cumulative impact of those actions.

At CVS Pharmacy the lever is CostVantage, its cost-based pricing model. Management credits it with a more consistent margin profile in a business squeezed by pharmacy reimbursement pressure. Same-store prescription volumes rose 7% in the second quarter of 2026, helped by the Rite Aid transaction. Growing scripts faster than the market, management says, creates operating leverage across its 9,000 stores.

The 2026 outlook assumes no share repurchases, so any lift in it is operational. Caremark, the pharmacy benefit manager, is the harder part.

Does The Caremark Headwind Swallow Aetna’s Gain?

Management named that problem itself. In 2027 it expects the 340B drug pricing headwind to continue and Caremark membership to fall. Some of that is its own deliberate approach to client renewals. Some of it is health plan customers exiting markets.

Having named both, the CFO still called an outlook of at least $8.44 in 2027 adjusted earnings per share reasonable. For 2026 itself the guidance went up $0.60, to a range of $7.90 to $8.10. That $8.44 is roughly 13% above an adjusted 2026 baseline of $7.46, which management calculates by starting at the guidance midpoint of $8.00 and stripping out $0.54 of favorable prior-year reserve development.

The case is narrow. You would be buying margin repair across two segments with a named 2027 headwind sitting in a third. The market has noticed: CVS Health has returned about 27% over the past year against 17% for the S&P 500, though the stock still trades at about 82% of its 52-week high. If the raise is what draws you, compare it against companies whose guidance keeps climbing.

So Is The Margin Repair Reason Enough To Own CVS Health?

Perhaps, but only if you are buying the repair itself. The case rests on both Aetna and CVS Pharmacy delivering on management’s targets, which compounds the execution risk across a single company. Our Five-Factor Stock Scorecard ranks every stock the same way on growth, profitability, stability, resilience, and valuation. And if you would rather not pick the name at all, look at the Trefis High Quality Portfolio. That portfolio has a track record of outpacing the three major indices.